Diamond Member Pelican Press 0 Posted July 1, 2025 Diamond Member Share Posted July 1, 2025 Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with chemotherapy (mFOLFOX6), achieved its primary goal of overall survival (OS) in individuals with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) *******. The combo showed OS improvement against placebo with chemotherapy in G/ This is the hidden content, please Sign In or Sign Up 0 Quote Link to comment https://hopzone.eu/forums/topic/279843-amgen-and-zai-lab%E2%80%99s-trial-of-gastric-cancer-therapy-m%E2%80%A6/ Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.